LCAR-C182A cells therapy

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameLCAR-C182A cells therapy

Drug Alias NameLCAR-C182ALCAR-C-182-A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CLDN18

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsStomach NeoplasmsCarcinoma, Pancreatic Ductal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesNanjing Legend Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNanjing Legend Biotechnology Co Ltd

Active IndicationsN/A

Inactive IndicationsStomach NeoplasmsCarcinoma, Pancreatic Ductal

Other Information

ATC CodeN/A